-DOCSTART- -X- O
Stavudine -X- _ O
( -X- _ O
d4T -X- _ O
) -X- _ O
was -X- _ O
, -X- _ O
until -X- _ O
recently -X- _ O
, -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
widely -X- _ O
prescribed -X- _ O
antiretroviral -X- _ O
drugs -X- _ O
worldwide. -X- _ O
While -X- _ O
there -X- _ O
has -X- _ O
been -X- _ O
a -X- _ O
major -X- _ O
shift -X- _ O
away -X- _ O
from -X- _ O
d4T -X- _ O
use -X- _ O
in -X- _ O
resource-limited -X- _ O
countries -X- _ O
, -X- _ O
a -X- _ O
large -X- _ O
number -X- _ O
of -X- _ O
patients -X- _ O
have -X- _ O
previously -X- _ O
received -X- _ O
( -X- _ O
or -X- _ O
continue -X- _ O
to -X- _ O
receive -X- _ O
) -X- _ O
d4T -X- _ O
, -X- _ O
and -X- _ O
many -X- _ O
have -X- _ O
developed -X- _ O
peripheral -X- _ O
neuropathy. -X- _ O
The -X- _ O
identification -X- _ O
of -X- _ O
genetic -X- _ O
predictors -X- _ O
of -X- _ O
increased -X- _ O
risk -X- _ O
might -X- _ O
suggest -X- _ O
novel -X- _ O
therapeutic -X- _ O
targets -X- _ O
for -X- _ O
such -X- _ O
patients. -X- _ O
In -X- _ O
AIDS -X- _ O
Clinical -X- _ O
Trials -X- _ O
Group -X- _ O
protocol -X- _ O
384 -X- _ B-Patient
, -X- _ I-Patient
antiretroviral-naïve -X- _ I-Patient
patients -X- _ I-Patient
were -X- _ O
randomized -X- _ O
to -X- _ O
d4T -X- _ B-Intervention
/ -X- _ I-Intervention
didanosine -X- _ I-Intervention
( -X- _ I-Intervention
ddI -X- _ I-Intervention
) -X- _ I-Intervention
- -X- _ I-Intervention
or -X- _ I-Intervention
zidovudine -X- _ I-Intervention
/ -X- _ I-Intervention
lamivudine- -X- _ I-Intervention
containing -X- _ I-Intervention
regimens. -X- _ I-Intervention
Data -X- _ O
from -X- _ O
d4T -X- _ O
/ -X- _ O
ddI -X- _ O
recipients -X- _ O
were -X- _ O
analyzed -X- _ O
for -X- _ O
genome-wide -X- _ O
associations -X- _ O
( -X- _ O
approximately -X- _ O
1 -X- _ O
million -X- _ O
genetic -X- _ O
loci -X- _ O
) -X- _ O
with -X- _ O
new -X- _ O
onset -X- _ O
distal -X- _ O
sensory -X- _ O
peripheral -X- _ O
neuropathy. -X- _ O
Analyses -X- _ O
involved -X- _ O
254 -X- _ O
patients -X- _ O
( -X- _ O
49 -X- _ O
% -X- _ O
White -X- _ O
, -X- _ O
34 -X- _ O
% -X- _ O
Black -X- _ O
, -X- _ O
17 -X- _ O
% -X- _ O
Hispanic -X- _ O
) -X- _ O
, -X- _ O
comprising -X- _ O
90 -X- _ B-Patient
peripheral -X- _ I-Patient
neuropathy -X- _ I-Patient
cases -X- _ I-Patient
( -X- _ I-Patient
32 -X- _ I-Patient
grade -X- _ I-Patient
1 -X- _ I-Patient
, -X- _ I-Patient
35 -X- _ I-Patient
grade -X- _ I-Patient
2 -X- _ I-Patient
, -X- _ I-Patient
23 -X- _ I-Patient
grade -X- _ I-Patient
3 -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
164 -X- _ B-Comparison
controls. -X- _ I-Comparison
After -X- _ B-Outcome
correcting -X- _ I-Outcome
for -X- _ I-Outcome
multiple -X- _ I-Outcome
comparisons -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
polymorphism -X- _ I-Outcome
was -X- _ I-Outcome
consistently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
neuropathy -X- _ I-Outcome
among -X- _ I-Outcome
all -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
among -X- _ I-Outcome
White -X- _ I-Outcome
, -X- _ I-Outcome
Black -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
Hispanic -X- _ I-Outcome
patients -X- _ I-Outcome
analyzed -X- _ I-Outcome
separately -X- _ I-Outcome
, -X- _ I-Outcome
both -X- _ I-Outcome
in -X- _ I-Outcome
genome-wide -X- _ I-Outcome
analyses -X- _ I-Outcome
( -X- _ I-Outcome
threshold -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
5.0 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
−8 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
focused -X- _ I-Outcome
on -X- _ I-Outcome
46 -X- _ I-Outcome
neuropathy- -X- _ I-Outcome
associated -X- _ I-Outcome
genes -X- _ I-Outcome
( -X- _ I-Outcome
threshold -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
3.5 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
−5 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
the -X- _ I-Outcome
latter -X- _ I-Outcome
analyses -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
lowest -X- _ I-Outcome
P -X- _ I-Outcome
values -X- _ I-Outcome
were -X- _ I-Outcome
in -X- _ I-Outcome
KIF1A -X- _ I-Outcome
among -X- _ I-Outcome
Whites -X- _ I-Outcome
( -X- _ I-Outcome
rs10199388 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
8.4 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
−4 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
LITAF -X- _ I-Outcome
among -X- _ I-Outcome
Blacks -X- _ I-Outcome
( -X- _ I-Outcome
rs13333308 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
6.0 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
−6 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
NEFL -X- _ I-Outcome
among -X- _ I-Outcome
Hispanics -X- _ I-Outcome
( -X- _ I-Outcome
rs17763685 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
5.6 -X- _ I-Outcome
× -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
−6 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Susceptibility -X- _ I-Outcome
to -X- _ I-Outcome
d4T -X- _ I-Outcome
/ -X- _ I-Outcome
ddI- -X- _ I-Outcome
associated -X- _ I-Outcome
neuropathy -X- _ I-Outcome
is -X- _ I-Outcome
not -X- _ I-Outcome
explained -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
single -X- _ I-Outcome
genetic -X- _ I-Outcome
variant -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
marked -X- _ I-Outcome
effect. -X- _ I-Outcome
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
doi:10.1007 -X- _ O
/ -X- _ O
s13365-014-0235-9 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

